Navigation Links
Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
Date:6/1/2009

ients with advanced solid tumors. The objectives of the study are to determine the maximum tolerated dose (MTD) as well as to assess safety and pharmacokinetics. The maximum tolerated dose is not yet defined and accrual to the study continues.

ASCO Poster Information

"A Phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors."

By E. Sausville, L. Garbo, G. J. Weiss, S. Anthony, D. Shkolny, A. V. Yurkovetskiy, C. Bethune, R. J. Fram; University of Maryland, Baltimore, MD; New York Oncology Hematology, Albany, NY; TGen Clinical Research Services, Scottsdale, AZ; Mersana Therapeutics, Inc., Cambridge, MA; Covance Bioanalytical, Madison, WI

    Session: Developmental Therapeutics: Cytotoxic Chemotherapy
    Type: General Poster Session
    Time: Saturday May 30, 2009, 8:00 AM to 12:00 PM
    Location: Level 2, West Hall C

About Fleximer(R)

The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Fleximer(R) technology improves the therapeutic index of existing compounds by uniquely combining biodegradability with "biological stealth" properties, making Fleximer(R) materials and their conjugates long-circulating and non-immunotoxic. Fleximer(R) molecules are characterized by solubility in water, with stability in common manufacturing procedures.

About Mersana Therapeutics, Inc.

Mersana Therapeutics employs its biodegradable polymer platform (Fleximer(R)) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partner
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
2. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"),a Xianyang-based developer, ... and conditions,today announced fiscal results for its second quarter ended June 30, 2009. ... Results, ... Q2 2009 Q2 ...
... ... Web 2.0 Website in an effort to not only provide circuit board assembly and design ... ... value to their current and future customers Surface Mount Solutions (SMS) has launched a new ...
... , , , ... ACTC) announced today that Dr. Robert Lanza, its Chief Scientific Officer, is ... 102 and 55 [Live Saturday 12 pm - 1 pm ET; Replays ... The show focuses on Dr. Lanza,s research at ACTC and his new ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 2Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 3Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 4Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 5Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 6Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 7Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 8Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 9Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 10Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 11Surface Mount Solutions Launches New Website 2Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 2Dr. Robert Lanza is Featured Guest on Deepak Chopra's SIRIUS XM Stars Radio Show 3
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... The way indigenous cultures around the globe use,traditional medicines ... linked to the,natural environment, new research has found. ... threat that comes on top of the challenges posed ... for more than half the world,s population, with 80 ...
... Energy,s (DOE,s) Office of Science and its labs will be ... AAAS Annual Meeting,CHICAGO Attendees of the 2014 AAAS Annual ... DOE,s Office of Science and its labs will play an ... President,s Address ,2014 AAAS co-chair ...
... PITTSBURGH, Feb. 13, 2014 University of Pittsburgh Cancer Institute ... to do new tricks., By screening a library of FDA-approved ... treatment for a rare type of cancer, UPCI scientists were ... the cancer becomes resistant to standard drug treatment., The discovery, ...
Cached Biology News:Environment change threatens indigenous know-how 2Department of Energy speakers and sessions at AAAS 2Department of Energy speakers and sessions at AAAS 3Department of Energy speakers and sessions at AAAS 4Department of Energy speakers and sessions at AAAS 5Department of Energy speakers and sessions at AAAS 6Laboratory detective work points to potential therapy for rare, drug-resistant cancer 2
... deparaffinize and perform Heat Induced Antigen Retrieval ... mounted on glass microscope slides. Deparffinization is ... high temperature used in HIER (over 90degrees ... by detergent. Formaldehyde fixation impairs or totally ...
... Bovine Calf Serum; U.S. ... seek an uncompromising quality; Low ... Collected from animals of US ... those who seek an uncompromising ...
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
...
Biology Products: